tak-041
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 27, 2016 (NCT02748694)
Timeline
Indications
Mechanism of action
GPR139 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tak-041
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05165394 | Phase 2 | Dec 31, 2021 | Neurocrine Biosciences |
| NCT03319953 | Phase 2 | Dec 21, 2017 | Takeda |
| NCT02959892 | Phase 1 | Jan 18, 2017 | Takeda |
| NCT02748694 | Phase 1 | Jun 27, 2016 | Takeda |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 3 | 3 | 2 | 2016 |
| Neurocrine Biosciences | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1